What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.61%
Annual Rate
CNY 0.10Paid annual
Payout Ratio
19.0%Sustainable
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.36BCNY
944.61M · vs all stocks (USD)
Updated Aug 20, 2026
Trailing P/E
31.30x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Revenue (TTM)
5.64BCNY
837.77M · vs all stocks (USD)
Updated Aug 20, 2026
Profit Margin
3.71%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Beta
0.7390x
vs all stocks
Updated Aug 20, 2026
52-Week Change
10.58%
vs all stocks
Updated Aug 20, 2026
Market Capitalization
6.36BCNY
944.61M · vs all stocks (USD)
Updated Aug 20, 2026
Enterprise Value
7.10BCNY
1.05B · vs all stocks (USD)
Updated Aug 20, 2026
Trailing P/E
31.30x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
PEG Ratio
1.06x
Updated Aug 20, 2026
Price to Sales (TTM)
1.18x
vs Pharmaceutical Retailers peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 1.13×.Updated Aug 20, 2026
Price to Book (MRQ)
3.05x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Enterprise to Revenue
1.26x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Enterprise to EBITDA
15.53x
vs Pharmaceutical Retailers peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 16.15×.Updated Aug 20, 2026
Gross Margin
35.14%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Profit Margin
3.71%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Operating Margin
8.64%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Return on Assets (TTM)
4.90%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Return on Equity (TTM)
10.75%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Revenue (TTM)
5.64BCNY
837.77M · vs all stocks (USD)
Updated Aug 20, 2026
Revenue per Share (TTM)
14.15CNYUpdated Aug 20, 2026
Quarterly Revenue Growth
12.20%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Gross Profit (TTM)
1.92BCNY
285.71M · vs all stocks (USD)
Updated Aug 20, 2026
EBITDA (TTM)
439.24MCNY
65.24M · vs all stocks (USD)
Updated Aug 20, 2026
Net Income (TTM)
209.47MCNY
31.11M · vs all stocks (USD)
Updated Aug 20, 2026
Quarterly Earnings Growth (YoY)
29.60%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Operating Cash Flow (TTM)
778.41MCNY
115.61M · vs all stocks (USD)
Updated Aug 20, 2026
Levered Free Cash Flow (TTM)
534.66MCNY
79.41M · vs all stocks (USD)
Updated Aug 20, 2026
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 20, 2026
Trailing Annual Dividend Yield
0.61%
vs all stocks
Updated Aug 20, 2026
Payout Ratio
19.04%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Minority Interest (Equity)
66.13MCNYFY2025 · Dec 31, 2025
Revenue
5.49BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
3.63BCNYFY2025 · Dec 31, 2025
Gross Profit
1.86BCNYFY2025 · Dec 31, 2025
Operating Income
412.96MCNY
61.33M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
294.39MCNYFY2025 · Dec 31, 2025
Income Tax Expense
80.52MCNYFY2025 · Dec 31, 2025
Net Income
213.87MCNYFY2025 · Dec 31, 2025
EBIT
324.61MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
751.95MCNYFY2025 · Dec 31, 2025
Research & Development
29.58MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
317.17MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
27.17MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
10.03MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
30.22MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.4800CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.4800CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
398.65MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
398.65MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
213.87MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-22.51MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-20.47MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-172.92MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
268.26MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
213.87MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
62.98MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-192.25MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-105.06MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-152.46MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-488.35MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.81BCNYFY2025 · Dec 31, 2025
Sale of Investments
1.81BCNYFY2025 · Dec 31, 2025
Other Investing Activity
469.99KCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-647.15MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
734.35MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-516.68MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-56.75MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-380.57MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-219.65MCNYFY2025 · Dec 31, 2025
Shares Outstanding
400.01MSharesUpdated Aug 20, 2026
Float Shares
136.44MSharesUpdated Aug 20, 2026
% Held by Insiders
64.55%
vs all stocks
Updated Aug 20, 2026
% Held by Institutions
4.67%
vs all stocks
Updated Aug 20, 2026
Total Cash (MRQ)
999.07MCNY
148.38M · vs all stocks (USD)
Updated Aug 20, 2026
Total Cash per Share (MRQ)
2.50CNYUpdated Aug 20, 2026
Total Debt (MRQ)
1.27BCNY
188.75M · vs all stocks (USD)
Updated Aug 20, 2026
Total Debt to Equity (MRQ)
0.5664x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Current Ratio (MRQ)
1.13x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Book Value per Share (MRQ)
5.44CNYUpdated Aug 20, 2026
Total Assets
5.49BCNY
815.13M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
2.91BCNYFY2025 · Dec 31, 2025
Total Liabilities
3.33BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
2.58BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
639.67MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
2.69BCNYFY2025 · Dec 31, 2025
Cash
260.11MCNYFY2025 · Dec 31, 2025
Cash Equivalents
694.44MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
954.55MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
22.00MCNYFY2025 · Dec 31, 2025
Accounts Receivable
565.83MCNYFY2025 · Dec 31, 2025
Inventory
1.05BCNYFY2025 · Dec 31, 2025
Accounts Payable
1.67BCNYFY2025 · Dec 31, 2025
Short-term Debt
724.37MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
9.96MCNYFY2025 · Dec 31, 2025
Long-term Debt
627.16MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
400.01MCNYFY2025 · Dec 31, 2025
Retained Earnings
724.04MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.16BCNY
321.26M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
0.00CNYFY2025 · Dec 31, 2025
52-Week Low
12.17CNYUpdated Aug 20, 2026
52-Week High
29.76CNYUpdated Aug 20, 2026
52-Week Change
10.58%
vs all stocks
Updated Aug 20, 2026
Beta
0.7390x
vs all stocks
Updated Aug 20, 2026
50-Day MA
15.05CNYUpdated Aug 20, 2026
200-Day MA
18.00CNYUpdated Aug 20, 2026
Avg 10-Day Volume
29.02MSharesUpdated Aug 20, 2026
Avg 30-Day Volume
22.25MSharesUpdated Aug 20, 2026
Diluted EPS (TTM)
0.5300CNYUpdated Aug 20, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 35.1%, higher than 95% of its Pharmaceutical Retailers peers (median 24.3%)Significant